Serum total prolactin and monomeric prolactin reference intervals determined by precipitation with polyethylene glycol: Evaluation and validation on common immunoassay platforms

Clinical Chemistry

Volumn 54, Issue 10, 2008, Pages 1673-1681

  Beltran, Luisa ^a   Fahie Wilson, Michael N ^a   McKenna, T Joseph ^b   Kavanagh, Lucille ^b   Smith, Thomas P ^b  

^a SOUTHEND HOSPITAL   (United Kingdom)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; PROLACTIN; MACROGOL DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE CLASSIFICATION; EVALUATION; FEMALE; GEL FILTRATION CHROMATOGRAPHY; HUMAN; HYPERPROLACTINEMIA; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PARAMETER; PATIENT CODING; PRECIPITATION; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REFERENCE VALUE; VALIDATION STUDY; BLOOD; CHEMISTRY; GEL CHROMATOGRAPHY; METHODOLOGY; STANDARD;

CHROMATOGRAPHY, GEL; FEMALE; HUMANS; IMMUNOASSAY; MALE; POLYETHYLENE GLYCOLS; PRECIPITATION; PROLACTIN; REFERENCE VALUES;

EID: 54049115142     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2008.105312     Document Type: Article

References (36)

1. Foglia G. Prolactinomas and hyperprolactinemic syndromes. In: De Groot LJ, Jameson JL, editors. Endocrinology. Vol. 4. Philadelphia (PA): W.B. Saunders; 2001. p. 329-42.
2. Mah PM, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med 2002;20:365-74.
3. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab 2005;90:3927-32.
4. Fahie-Wilson MN, Soule SG. Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem 1997;34:252-8.
5. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf) 1999;51:119-26.
6. Leslie H, Courtney CH, Bell PM, Hadden DR, McCance DR, Ellis PK, et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab 2001;86:2743-6.
7. Strachan MW, Teoh WL, Don-Wauchope AC, Seth J, Stoddart M, Beckett GJ. Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol (Oxf) 2003;59:339-46.
8. Fraser IS, Lun ZG, Zhou JP, Herington AC, McCarron G, Caterson I, et al. Detailed assessment of big big prolactin in women with hyperprolactinemia and normal ovarian function. J Clin Endocrinol Metab 1989;69:585-92.
9. Hattori N, Inagaki C. Anti-prolactin (PRL) autoantibodies cause asymptomatic hyperprolactinemia: bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab 1997;82:3107-10.
10. Larrea F, Villanueva C, Carmen Cravioto M, Escorza A, del Real O. Further evidence that big, big prolactin is preferentially secreted in women with hyperprolactinemia and normal ovarian function. Fertil Steril 1985;44:25-30.
11. Smith TP, Suliman AM, Fahie-Wilson MN, McKenna TJ. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab 2002;87:5410-5.
12. Schneider W, Marcovitz S, Al-Shammari S, Yago S, Chevalier S. Reactivity of macroprolactin in common automated immunoassays. Clin Biochem 2001;34:469-73.
13. Cavaco B, Prazeres S, Santos MA, Sobrinho LG, Leite V. Hyperprolactinemia due to big big prolactin is differently detected by commercially available immunoassays. J Endocrinol Invest 1999;22:203-8.
14. Fahie-Wilson MN. Detection of macroprolactin causing hyperprolactinemia in commercial assays for prolactin. Clin Chem 2000;46:2022-3.
15. Suliman AM, Smith TP, Gibney J, McKenna TJ. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem 2003;49:1504-9.
16. Olukoga AO, Dornan TL, Kane JW. Three cases of macroprolactinaemia. J R Soc Med 1999;92:342-4.
17. Heaney AP, Laing I, Walton L, Seif MW, Beardwell CG, Davis JR. Misleading hyperprolactinaemia in pregnancy. Lancet 1999;353:720.
18. Guay AT, Sabharwal P, Varma S, Malarkey WB. Delayed diagnosis of psychological erectile dysfunction because of the presence of macroprolactinemia. J Clin Endocrinol Metab 1996;81:2512-4.
19. Cattaneo FA, Fahie-Wilson MN. Concomitant occurrence of macroprolactin, exercise-induced amenorrhea, and a pituitary lesion: a diagnostic pitfall [Case Report]. J Neurosurg 2001;95:334-7.
20. Whittaker PG, Wilcox T, Lind T. Maintained fertility in a patient with hyperprolactinemia due to big, big prolactin. J Clin Endocrinol Metab 1981;53:863-6.
21. Leite V, Cosby H, Sobrinho LG, Fresnoza MA, Santos MA, Friesen HG. Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin Endocrinol (Oxf) 1992;37:365-72.
22. Fahie-Wilson MN, John R, Ellis AR. Macroprolactin; high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005;42:175-92.
23. Sturgeon CM, Ellis AR, Al-Sadie R, Logan M, Costa M. UK NEQAS for Peptide Hormones Annual Review 2006. Edinburgh: UK NEQAS; 2007. 15 p.
24. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD, Brue T. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006;65:265-73.
25. Schlechte JA. The macroprolactin problem. J Clin Endocrinol Metab 2002;87:5408-9.
26. Fahie-Wilson M. In hyperprolactinemia, testing for macroprolactin is essential. Clin Chem 2003;49:1434-6.
27. Kavanagh L, McKenna TJ, Fahie-Wilson M, Gibney J, Smith TP. Specificity and clinical utility of methods for the detection of macroprolactin. Clin Chem 2006;52:1366-72.
28. Vieira JG, Tachibana TT, Obara LH, Maciel RM. Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin Chem 1998;44:1758-9.
29. Fahie-Wilson MN, Dearman G. The Beckman Access prolactin assay and macroprolactin; prevalence and detection of hyperprolactinaemia due to macroprolactin. Clin Chem 2005;51 Suppl: A231.
30. Sale JK, Fahie-Wilson MN. Macroprolactin and the DPC Immulite 2000 prolactin assay: characteristics of the reaction and detection by precipitation with polyethylene glycol [abstract from national meeting proceedings]. London: Association of Clinical Biochemists; 2002. p. 78.
31. Craddock HS, Fahie-Wilson M, Heys AD. Macroprolactin detection by ultrafiltration screening with the Abbott AxSYM assay [abstract from national meeting proceedings]. London: Association of Clinical Biochemists; 2000. p. 148.
32. Ellis MJ, Livesey JH, Soule SG. Macroprolactin, big-prolactin and potential effects on the misdiagnosis of hyperprolactinemia using the Beckman Coulter Access Prolactin assay. Clin Biochem 2006;39:1028-34.
33. Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf) 2005;62:633-43.
34. Solberg HE. The IFCC recommendation on estimation of reference intervals: the RefVal programme. Clin Chem Lab Med 2004;42:710-4.
35. Fahie-Wilson M, Bieglmayer C, Kratzsch J, Nusbaumer C, Jurgen Roth H, Zaninotto M, et al. Roche Elecsys prolactin II assay: Reactivity with macroprolactin compared with eight commercial assays for prolactin and determination of monomeric prolactin by precipitation with polyethyleneglycol. Clin Lab 2007;53:485-92.
36. Klee G. Special ligands: participant summary report. Northfield (IL): College of American Pathologists; 2007. p. 11.